Incidence, Risk Factors, and Renal Outcomes of Cancer Patients Treated With Immune Checkpoint Inhibitor: A Retrospective Cohort Study in a Single Tertiary Hospital in the Philippines
Sep 2026· Philippine journal of internal medicine· Vol 64, pp. 24-32· 0 citations
TL;DR
This study showed that the incidence of ICI AKI was at 3.8%.
Abstract
Introduction: Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target inhibitory receptors expressed on T cells and are associated with a variety of immune-related adverse events (irAE) including the kidneys. This study attempted to determine the factors, incidence, electrolyte and urine abnormalities, clinical outcomes, and development of chronic kidney disease (CKD) among patients who developed immune checkpoint inhibitor-associated acute kidney injury (ICI AKI).
Methodology: Single-center retrospective cohort study of cancer patients receiving ICI between January 2018 and December 2024 at St. Luke's Medical Center Quezon City, Philippines. To be included, patients must have cancer, at least 18 years old, and had to receive ≥ 1 dose of ICI. They were excluded if they are already on renal replacement therapy (RRT), no baseline serum creatinine (sCr) prior to giving the first dose of ICI, or sCr after the 1st dose or ≥ 3 months after administration of ICI.
Results: Among the 210 patients treated with ICI, 8 (3.8%) developed ICI AKI. Among the patients treated with ICI, a total of 14.29% (30) patients developed AKI. Among those who developed AKI, 53.33% (16) of patients progressed to chronic kidney disease and in patients who developed ICI AKI, 37.5% progressed to CKD. Urinalysis also showed that 39.52% (83) of patients had hematuria and 44.76% (94) had proteinuria. Moreover, 34.3% (72) of patients had electrolyte abnormalities with the most common electrolyte abnormality being hyponatremia at 25.7%.
Conclusion and Recommendation: This study showed that the incidence of ICI AKI was at 3.8%. The most common electrolyte abnormality was hyponatremia and among patients who developed ICI AKI, 37.5% progressed to CKD. No statistically significant risk factor was associated with the development of ICI-AKI. However, interpretation of these findings should be approached with caution given the small number of ICI-AKI events (n = 8), which limited the statistical power of the analysis and resulted in wide confidence intervals for several estimates. A prospective multicenter cohort study may be done in the future.
Keywords: Immune checkpoint inhibitor associated acute kidney injury, acute kidney injury, chronic kidney disease
Background
Acute kidney injury (AKI) is a common complication in patients receiving immune checkpoint inhibitor (ICI) therapy. It can result from conventional causes or immune-mediated mechanisms. This study aimed to determine the incidence, risk factors, and clinical outcomes of all-cause AKI in patients treated with...
Yuri Seo, Ho-Jin Lee, Y. Choi et al.· Kidney Research and Clinical...· 0 citations
Findings support proactive cardiovascular risk assessment and optimization in long-term survivors while reinforcing that the excess risk is modest and should not deter use of these life-prolonging therapies.
I. Nardi Agmon, V. Giannakeas, Y. Kaliwal et al.· European Heart Journal· 0 citations
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but may cause immune-related kidney injury, and their association with glomerular disease remains incompletely understood. We evaluated the risk of incident glomerular disease following ICI therapy using the TriNetX U.S. Collaborative Network. Adult...
Immune checkpoint inhibitors (ICI) have transformed outcomes for patients with advanced melanoma but are associated with acute kidney injury (AKI), including immune-related (IR) nephritis, which may lead to treatment interruption, immunosuppression, and adverse kidney and oncological outcomes.
To describe in...
A. Bendall, F. Martin, N. Kennedy et al.· Journal of Onco-Nephrology· 0 citations
Background:
Immune checkpoint inhibitors (ICIs) have transformed treatment across multiple solid tumors, but immune-related adverse events (irAEs) occur in approximately 40% of treated patients across all grades and require prompt recognition to limit morbidity. In settings with a high patient-to-oncologist ratio, nu...
E. Thomas, Ancy Varughese, Simi Pathrose· Integrated Oncology Diagnost...· 0 citations
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet their efficacy and safety in patients with chronic kidney disease (CKD) remain uncertain, as this population is frequently excluded from pivotal trials. We aimed to evaluate clinical outcomes of ICI therapy in patients with cancer and CKD....
R. Pereira Silva, M. Lourenço Ferreira, Davi R. S. G. Amorim et al.· Journal of Onco-Nephrology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.